

Homo sapiens Dullard Protein Phosphatase Shows a Preference for the Insulin-Dependent Phosphorylation Site of Lipin1

Rui Wu,[†] Megan Garland,[†] Debra Dunaway-Mariano,^{‡,*} and Karen N. Allen^{†,*}

[†]Department of Chemistry, Boston University, 590 Commonwealth Avenue, Boston, Massachusetts 02215, United States

[‡]Department of Chemistry and Chemical Biology, University of New Mexico, Albuquerque, New Mexico 87131, United States

S Supporting Information

ABSTRACT: Human lipin1 catalyzes the highly regulated conversion of phosphatidic acids to diacylglycerides. Lipin's cellular location, protein partners, and biological function are directed by phosphorylation—dephosphorylation events catalyzed by the phosphoserine phosphatase dullard. To define the determinants of dullard substrate recognition and catalysis, and hence, lipin regulation, steady-state kinetic analysis was performed on phosphoserine-bearing nonapeptides based on the phosphorylation sites of lipin. The results demonstrate that dullard shows specificity for the peptide corresponding to the insulin-dependent phosphorylation site (Ser106) of lipin with a k_{cat}/K_m of $2.9 \times 10^4 \text{ M}^{-1} \text{ s}^{-1}$. These results are consistent with a coil-loop structure for the insulin-dependent phosphorylation site on human lipin1 and make unlikely the requirement for an adaptor protein to confer activity such as that proposed for the yeast homologue.

Human lipin acts as a phosphatidic acid (PA) phosphohydrolase.¹ It is considered to be one of the key regulators of cellular lipid metabolism in myelinated motor neurons and in a variety of tissues, including adipose, liver, and muscle.^{2–4} Three lipin isoforms exist in higher eukaryotes, dubbed lipin1, lipin2, and lipin3. Identification of the genetic mutation responsible for the fatty liver dystrophic mouse phenotype¹ led to a single-site mutation in the lipin1 protein (Gly84Arg) and ultimately to the assignment of its catalytic activity. Polymorphisms in the lipin1 and lipin2 genes are associated with various disease states.^{5–8} Notably, a variation in the lipin1 gene that causes an amino acid substitution within the phosphatase catalytic domain is linked to statin-induced myopathy.⁹ Lipin1 is a large (890 residues in humans), multidomain protein comprised of a predicted N-terminal domain (NLIP) of unknown structure, an intervening segment that includes a serine-rich domain, and a C-terminal phosphatase domain, which are homologous (Figure 1) to the catalytic domain of the haloalkanoate dehalogenase superfamily (HADSf), a large ubiquitous superfamily made up mostly of phosphatases.^{10,11}

Phosphorylation is a regulator of lipin1 cellular location. In humans, a specific phosphatase, dullard, catalyzes the hydrolysis of lipin O γ -phosphoryl serines (pSer). Similarly, the yeast orthologue of dullard, Nem1, acts on the yeast lipin orthologue

Smp2.¹² Notably, dullard and Nem1 are also members of the HADSf. Sequence analysis shows that although they differ in length (244 and 446 residues for human dullard and *Saccharomyces cerevisiae* Nem1, respectively) each is comprised of an N-terminal 22-amino acid transmembrane helix and a C-terminal HADSf domain that conserves all four of the expected catalytic motifs involved in phosphoryl transfer. Alignment of human dullard and *S. cerevisiae* Nem1 HADSf domains (residues 235–446) shows that they are homologous (45% identical and 68% similar in sequence). The phosphatase activity of dullard and Nem1 is intimately linked to the function of lipin1 and Smp2.^{13,14} Yeast cells lacking active Nem1 phosphatase exhibit the phenotype characteristic of Smp2 knockout, namely, derepression of phospholipid synthesis genes and massive expansion of the nuclear membrane and endoplasmic reticulum (ER) membrane.¹² Lipin phosphorylation is hypothesized to prevent accessibility of substrate to the ER and nuclear membranes yet to have no impact on the PA hydrolase activity. A survey measuring relative activities of dullard toward an array of 360 phosphopeptides *in vitro* showed a marked preference for dullard toward pSer-containing peptides over phosphothreonine- or phosphotyrosine-containing peptides.¹⁴ Although numerous sites of phosphorylation have been identified in lipin1 and yeast Smp2, Ser106 of lipin1 appears to be a major site of insulin-stimulated phosphorylation.¹⁵ The preference of dullard and Nem1 for one pSer site over another has not been examined.

An apparent paradox discovered upon analyzing the *in vitro* activities of Nem1 and dullard is the dependence of Nem1 activity in yeast on the presence of protein Spo7, a multipass integral membrane protein. Reportedly, on the basis of pull-down experiments, Spo7 was found to bind to Nem1 at the C-terminal catalytic domain. Furthermore, deletion of Spo7 leads to a phenotype similar to that for deletion of Nem1, resulting in the accumulation of the phosphorylated form of Smp2 and nuclear membrane proliferation.¹⁶ Moreover, in the presence but not in the absence of Spo7, Nem1 shows *in vitro* catalytic activity against *p*-nitrophenyl phosphate (pNPP).¹² On the basis of our understanding of HADSf phosphatase structure and mechanism, it is unclear how Spo7 might stimulate Nem1-catalyzed dephosphorylation of pNPP.

Herein, we provide steady-state kinetic evidence that heterologously expressed human dullard (lacking the N-terminal transmembrane helix) acts on nonapeptides corresponding to the human lipin1 sequence with high specificity toward the peptide

Received: March 5, 2011

Published: March 17, 2011




Figure 1. Schematic diagram of human lipin1 with domains delimited. Sites of serine phosphorylation selected for peptide screening are marked.



Figure 2. Ribbon diagrams of the homology model of dullard (left) and X-ray crystal structures of Mg(II)-dependent phosphatase 1 (center) and the phosphatase domain of polynucleotide kinase/phosphatase (right). The conserved Rossmann fold of the HADSF is colored blue, and inserted segments are colored yellow, with the catalytic nucleophile colored red to mark the active site.

corresponding to the sequence flanking Ser106. The *in vitro* activity of the human dullard shows no requirement for a Spo7 orthologue.

We began our study of the dullard–lipin1 interaction by creating and examining a model of the three-dimensional structure of dullard. The objective was to determine whether the dullard active site is configured to bind an extended versus folded pSer-bearing sequence. Accordingly, a sequence homology threading model was generated in PHYRE using as the template the structure of the RNA polymerase C-terminal domain (CTD) phosphatase, Scp1 (PDB entry 1TA0; spanning residues 77–256 that comprise the HADSF domain)¹⁷ that is 45% identical in sequence to dullard. Residues 46–244 corresponding to the dullard sequence without the N-terminal transmembrane helix were modeled. The high degree of sequence identity and lack of extensive gaps in the alignment of the two sequences (Figure S1 of the Supporting Information) are indicative of a reliable model. In addition to the sequence similarity, there is similarity in the physiological functions of Scp1 and dullard, as Scp1 dephosphorylates the pSerS site on the C-terminal domain of RNA polymerase.¹⁸ HADSF members dullard and Scp1 are expected to share the same catalytic domain architecture, which includes the active site DXD nucleophile/general acid/base and the Mg²⁺ binding motifs essential for phosphoryl transfer.¹⁰ The model for dullard has accessibility to the active site similar to those of others in the HADSF that are believed to form a protein–protein¹⁹ or protein–polynucleotide²⁰ interface (Figure 2). This finding is consistent with either a protein surface interaction between dullard and lipin or an extended peptide chain interaction.

If dullard is similar to Scp1 in its mode of substrate recognition, it is expected that there will be conservation of the substrate-binding residues in the active site. The mode of substrate binding and the specificity determinants of Scp1 have been revealed via




Figure 3. Dullard model (red, stringently conserved) shown as a coil (left) and in space-filling representation (center and right) with peptide (cyan sticks) from Scp1 overlaid (right) by superimposing the Scp1 9-mer peptide complex structure (PDB entry 2GHQ) onto the dullard model and removing the Scp1 protein.

X-ray crystal structures of an inactive Scp1-D96N mutant (oblating phosphoaspartyl intermediate formation) bound with pSer containing 9- and 14-mer peptides, which incorporate selected regions of the RNA polymerase CTD sequence.²¹ The structures are consistent with a mode of interaction in which the extended RNA polymerase CTD threads through the Scp1 active-site canyon. Peptide binding is conferred by coordination of the phosphoryl group by the cofactor Mg²⁺ and by interactions with a hydrophobic groove formed between the catalytic domain and the inserted segments (comprised of Phe106, Val118, Ile120, Val127, and Leu155).²¹ Mapping of the stringently conserved residues of dullard obtained from a sequence alignment of all eukaryotic orthologues (Figure S2 of the Supporting Information) onto the homology model of dullard shows that the substrate-binding cleft is retained (Figure 3), with a similar active site groove comprised of residues His77, Val97, Ile99, Phe106, and Met134 stringently conserved among vertebrates. The mode and site of pSer peptide binding are then, most likely conserved between Scp1 and dullard. Because this finding indicates that dullard is targeting pSer residues located on solvated regions that are free to associate with the peptide-binding cleft, a kinetic analysis of nonapeptides based on lipin pSer sites was undertaken.

Dullard, lacking the N-terminal transmembrane domain (dullard 46–244, consistent with that portion of dullard modeled) was prepared as a recombinant protein and heterologously expressed in *Escherichia coli* (see the Supporting Information). The resulting >95% pure (as assessed by SDS–PAGE) dullard 46–244 was used in steady-state kinetic experiments to determine the specificity constants ($k_{\text{cat}}/K_{\text{m}}$) for dullard-catalyzed dephosphorylation of lipin-derived pSer peptides. On the basis of the documented specificity of Scp1 for SPTpSP peptides²¹ and the conservation of a substantial fraction of the residues that form the peptide binding pocket in dullard and Scp1, Pro/Thr/Ser-containing phosphoserine nonapeptides that represent lipin phosphorylation sites^{22–24} were tested as substrates. The 2-amino-6-mercapto-7-methylpurine riboside (MESG)-coupled phosphatase assay (Enzcheck assay kit) and molybdate green assay (Biomol Green assay kit) were employed as independent methods for monitoring dullard-catalyzed release of phosphate from peptides.

The steady-state kinetic results (Table 1) are consistent with recognition by dullard of specific solvated regions of lipin1 and with dullard specificity similar to that of the CTD phosphatase. The highest $k_{\text{cat}}/K_{\text{m}}$ value ($2.9 \times 10^4 \text{ M}^{-1} \text{ s}^{-1}$) was obtained for the peptide corresponding to the insulin-dependent

Table 1. Steady-State Kinetic Characterization of Dullard 46–244^a

lipin-derived phosphopeptide	peptide sequence	K_m (μ M)	k_{cat} (s^{-1})	k_{cat}/K_m ($M^{-1} s^{-1}$)
S106	HLAT(pS)PILS	32 ± 3 (50 ± 5)	0.92 ± 0.02 (1.38 ± 0.04)	2.9 × 10 ⁴ (2.8 × 10 ⁴)
S110	PIL(pS)EGASR	260 ± 50 (700 ± 100)	0.17 ± 0.01 (0.28 ± 0.02)	6.5 × 10 ² (4.0 × 10 ²)
S176	DNMNT(pS)EDE	~15000	>1 (>0.5)	
S248	SGSRP(pS)TP	32 ± 6 (700 ± 300)	0.024 ± 0.005 (0.01 ± 0.002)	7.5 × 10 ² (1.4 × 10)
S455	VEST(pS)DGLR	~10000	>1.4 (>1.6)	
S632	LRLT(pS)EQLK	2300 ± 700 (~1000)	1.8 ± 0.3 (>0.5)	4.3 × 10 ²

^a K_m and k_{cat} values were measured using the MESG-coupled phosphatase assay (EnzChek phosphate assay kit E-6646) at 25 °C. Values in parentheses were measured using the Biomol Green phosphate reagent at 25 °C.

phosphorylation site at Ser106, HLAT(pS)PILS. The reactivity of dullard toward the S106 peptide was ~40 times greater in k_{cat}/K_m than that of the next most reactive peptide (S248). In comparison, dullard-catalyzed hydrolysis of the “generic” substrate pNPP has a low k_{cat}/K_m of 56 $M^{-1} s^{-1}$ (k_{cat} = 1 s^{-1} , and K_m = 18 mM).¹⁴ The specificity of dullard is similar to that of Scp1 for its preferred peptide substrates [e.g., k_{cat}/K_m = 1.0 × 10⁴ $M^{-1} s^{-1}$ for PSYSPT(pS)PS].²¹ Notably, the preference for the T(pS)P sequence is shared between the two phosphatases. Taken together, these results suggest that dullard is targeting pSer106 and that this insulin-dependent phosphorylation site is most likely located within an unstructured (i.e., extended and solvated) region of lipin. Indeed, Ser106 is located in a region at the C-terminal end of the NLIP domain¹ with no predicted structure (Figure 1).

The specificity and high catalytic efficiency of dullard toward lipin-derived peptides measured by the *in vitro* assays herein suggest that human dullard does not require an adaptor/accessory protein for activity. Notably, whereas Spo7 homologues are pervasive in yeast and plant species, we were unable to identify such a Spo7 homologue in humans. The observation that dullard and Nem1 as well as Spo7 are predicted to be membrane-bound, and the phosphorylated substrate lipin and Smp2 are cytosolic proteins, introduces an intriguing possibility, that of regulation of activity by proximity. In yeast, Spo7 is posited to function as an essential adaptor. In humans, such an adaptor, if it exists, remains to be discovered.

■ ASSOCIATED CONTENT

S Supporting Information. Figures S1–S3 showing sequence alignments and protein purity as well as detailed protocols for cloning, expression, purification, and steady-state kinetics. This material is available free of charge via the Internet at <http://pubs.acs.org>.

■ AUTHOR INFORMATION

Corresponding Author

*K.N.A.: e-mail, drkallen@bu.edu; phone, (617) 358-5544; fax, (202) 354-5386. D.D.-M.: e-mail, dd39@unm.edu; fax, (505) 277-2609.

Funding Sources

This work was supported by National Institutes of Health Grants GM061099 and GM093342 (to K.N.A. and D.D.-M.) M.G. was supported by the Boston Undergraduate Research Opportunities Program.

■ ABBREVIATIONS

CTD, C-terminal domain; ER, endoplasmic reticulum; HADSF, haloalkanoate dehalogenase superfamily; MESG, 2-amino-6-

mercapto-7-methylpurine riboside; NLIP, lipin N-terminal domain; PA, phosphatidic acid; PDB, Protein Data Bank; pSer, O γ -phosphorylserine; pS, O γ -phosphorylserine; pNPP, *p*-nitrophenyl phosphate.

■ REFERENCES

- (1) Peterfy, M., Phan, J., Xu, P., and Reue, K. (2001) *Nat. Genet.* 27, 121.
- (2) Finck, B. N., Gropler, M. C., Chen, Z., Leone, T. C., Croce, M. A., Harris, T. E., Lawrence, J. C., Jr., and Kelly, D. P. (2006) *Cell Metab.* 4, 199.
- (3) Peterfy, M., Phan, J., and Reue, K. (2005) *J. Biol. Chem.* 280, 32883.
- (4) Phan, J., and Reue, K. (2005) *Cell Metab.* 1, 73.
- (5) Reue, K. (2009) *Curr. Opin. Lipidol.* 20, 165.
- (6) Reue, K., and Brindley, D. N. (2008) *J. Lipid Res.* 49, 2493.
- (7) Reue, K., and Dwyer, J. R. (2009) *J. Lipid Res.* 50 (Suppl.), S109.
- (8) Zeharia, A., Shaag, A., Houtkooper, R. H., Hindi, T., de Lonlay, P., Erez, G., Hubert, L., Saada, A., de Keyser, Y., Eshel, G., Vaz, F. M., Pines, O., and Elpeleg, O. (2008) *Am. J. Hum. Genet.* 83, 489.
- (9) Sirvent, P., Mercier, J., and Lacampagne, A. (2008) *Curr. Opin. Pharmacol.* 8, 333.
- (10) Allen, K. N., and Dunaway-Mariano, D. (2004) *Trends Biochem. Sci.* 29, 495.
- (11) Allen, K. N., and Dunaway-Mariano, D. (2009) *Curr. Opin. Struct. Biol.* 19, 658.
- (12) Santos-Rosa, H., Leung, J., Grimsey, N., Peak-Chew, S., and Siniosoglou, S. (2005) *EMBO J.* 24, 1931.
- (13) Han, G. S., Siniosoglou, S., and Carman, G. M. (2007) *J. Biol. Chem.* 282, 37026.
- (14) Kim, Y., Gentry, M. S., Harris, T. E., Wiley, S. E., Lawrence, J. C., Jr., and Dixon, J. E. (2007) *Proc. Natl. Acad. Sci. U.S.A.* 104, 6596.
- (15) Harris, T. E., Huffman, T. A., Chi, A., Shabanowitz, J., Hunt, D. F., Kumar, A., and Lawrence, J. C., Jr. (2007) *J. Biol. Chem.* 282, 277.
- (16) Siniosoglou, S., Santos-Rosa, H., Rappsilber, J., Mann, M., and Hurt, E. (1998) *EMBO J.* 17, 6449.
- (17) Kamenski, T., Heilmeyer, S., Meinhart, A., and Cramer, P. (2004) *Mol. Cell* 15, 399.
- (18) Yeo, M., Lin, P. S., Dahmus, M. E., and Gill, G. N. (2003) *J. Biol. Chem.* 278, 26078.
- (19) Peisach, E., Selengut, J. D., Dunaway-Mariano, D., and Allen, K. N. (2004) *Biochemistry* 43, 12770.
- (20) Galburt, E. A., Pelletier, J., Wilson, G., and Stoddard, B. L. (2002) *Structure* 10, 1249.
- (21) Zhang, Y., Kim, Y., Genoud, N., Gao, J., Kelly, J. W., Pfaff, S. L., Gill, G. N., Dixon, J. E., and Noel, J. P. (2006) *Mol. Cell* 24, 759.
- (22) O'Hara, L., Han, G. S., Peak-Chew, S., Grimsey, N., Carman, G. M., and Siniosoglou, S. (2006) *J. Biol. Chem.* 281, 34537.
- (23) Peterfy, M., Harris, T. E., Fujita, N., and Reue, K. (2010) *J. Biol. Chem.* 285, 3857.
- (24) Karanasios, E., Han, G.-S., Xu, Z., Carman, G. M., and Siniosoglou, S. (2010) *Proc. Natl. Acad. Sci. U.S.A.* 107, 17539.